CytoDyn Inc.

FOR THE LATEST DEVELOPING NEWS Click Here

Enrollment Locations for Open Label Extension (OLE)

Dr. Yang – Leronlimab in IDSA Publication

Brazil has approved critically ill COVID Phase 3 to begin

Leronlimab COVID-19 Brazil Trial enrolled the first patient

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab and Glioblastoma - Published April 2021

Leronlimab/Receptor Occupancy - Published

Leronlimab Published in Journal of Translational Autoimmunity

Nature Communications: Leronlimab and HIV
Case Study - Journal of Translational Autoimmunity

Dr. Seethamraju - Special isirv-AVG Virtual Conference

TNBC Presentation – Dr. Kelly

Leronlimab Potential in HIV PrEP

CytoDyn reveals results for cancer and NASH patients

Long-Hauler Trial Endpoints

Oncology Presentation

CCR5 closes the 1 temporal window for memory linking

CD15 Patients’ Testimonies

CytoDyn to Hold Webcast and Live Q/A on October 26

Annual Meeting of Stockholders – Wednesday, November 24

We believe in the future of precision medicine

CytoDyn believes in the future of precision medicine... more specificity, less side effects. Our target, the CCR5 receptor, has been implicated in multiple disease processes from HIV, GVHD, NASH, stroke recovery, multiple sclerosis, Parkinson's disease, to metastatic cancer. Leronlimab, our CCR5 antagonist, is a once a week, subcutaneous injection. One molecule with multiple opportunities. With precision comes the opportunity for improved safety, convenience, and enhanced efficacy for the patient.

Welcome to the future of target specific, precision medicine. Welcome to CytoDyn.

We are a biotechnology company focused on developing innovative treatments for multiple therapeutic indications. Our lead candidate Leronlimab (PRO 140) belongs to a new class of therapeutics called viral-entry inhibitors and is one of the most advanced experimental monoclonal antibodies for HIV treatment.

Leronlimab’s Mechanism of Action for Immuno-oncology

About Our Company

Arrow Down

Leronlimab for HIV

A Fully Humanized Monoclonal Antibody

Leronlimab (PRO 140) is a fully humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T cells. Leronlimab (PRO 140) only blocks the precise site on CCR5 that HIV needs to enter the cell without interfering with the normal functions of CCR5.

Read More on Leronlimab

CCR5 for Cancer

Developing CCR5 Technology in Cancer Indications

Based on the work of a leading oncologist and researcher who has played an instrumental role in identifying the role of CCR5 in cancer indications, we continue to develop CCR5 technology and have obtained promising results from various pre-clinical studies.

Read More on CCR5

The Science of Developing Monoclonal Antibodies

In the 1980s, a team of scientists developed a technique that fused a common type of tumor cell with a single mouse antibody-producing cell. The resulting hybrid cells all secreted the exact same antibody as the original mouse antibody-producing cell and thus came to be known as monoclonal antibodies. Since then, monoclonal antibodies have come to represent one of the fastest expanding opportunities in the biotechnology/pharma sector.

Learn About Our Science

Latest News

View all news

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow

Read More

CytoDyn Announces Preliminary Results from 2021 Annual Meeting

Read More

Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec

Read More